Zencurix Obtains European Certification for 6 Companion Diagnostics Including Lung, Colorectal, and Endometrial Cancer

[Asia Economy Reporter Hyungsoo Park] Genecurix announced on the 21st that it has obtained the European Conformity (CE) certification for six companion diagnostic products for cancers including lung cancer and colorectal cancer.

The digital PCR-based companion diagnostic product line, 'Droplex,' consists of test products targeting six biomarkers for lung cancer, colorectal cancer, endometrial cancer, breast cancer, thyroid cancer, and others. With the European certification, it is evaluated that Genecurix has succeeded in establishing one of the world's leading portfolios in the digital PCR-based companion diagnostics field. The newly launched lung cancer companion diagnostic kit, 'Droplex EGFR,' is highly anticipated as it enables liquid biopsy, which has strong market demand.

Companion diagnostics is a diagnostic method that identifies patient genomic information to determine in advance whether a specific drug will be effective for the patient. Since most targeted anticancer drugs are expensive and have side effects, the importance of companion diagnostics to assess patient treatment efficacy before administering anticancer drugs is increasing. Recently, new drug development companies are also collaborating with companion diagnostic companies to increase the clinical success rate of anticancer drug development.

Genecurix is also strengthening cooperation with new drug development companies and is proceeding with procedures to obtain certifications in various countries worldwide. It is also enhancing partnerships with global diagnostic equipment companies. Diagnostic equipment company Bio-Rad conducted training on Genecurix's Droplex products for sales and marketing personnel in major Asian countries last year and this year. Earlier this year, Genecurix signed an equipment distribution agreement with Bio-Rad.

A company official stated, "Based on the European certification, we expect the overseas export of Droplex products to be in full swing," and added, "We also plan to complete the domestic Ministry of Food and Drug Safety approval for major companion diagnostic products this year."

This content was produced with the assistance of AI translation services.